A Study to Describe the Experience of Both Patients and Their Clinicians in the Treatment of Fabry Disease With Enzyme Replacement Therapy.

  • STATUS
    Recruiting
  • days left to enroll
    38
  • participants needed
    120
  • sponsor
    Amicus Therapeutics
Send
Updated on 24 March 2022
See if I qualify
replacement therapy
agalsidase beta
agalsidase alfa

Summary

This is an international, non-interventional research study of adult patients with Fabry Disease and their caregivers. The study will comprise a prospective time and motion evaluation and a cross-sectional evaluation of patient and caregiver-reported outcomes. The study will evaluate the time associated with the preparation and administration of a single dose of ERT in patients by health care providers as well as the impact on Fabry patients and caregivers time and costs associated with an ERT treatment. The study will also evaluate the patients' quality of life wellbeing, fatigue and work productivity.

Details
Condition Fabry Disease
Treatment agalsidase beta, Agalsidase Alpha
Clinical Study IdentifierNCT04281537
SponsorAmicus Therapeutics
Last Modified on24 March 2022

Eligibility

 Yes No Not Sure

Inclusion Criteria

Patients with a documented diagnosis of FD
Patients who have received ≥4 doses of ERT (with agalsidase alfa or agalsidase beta) for the treatment of FD
Patients who present to the participating hospital(s) or treatment centre(s) for administration of a dose of ERT (as part of their routine treatment) during the data collection period
Caregiver Inclusion Criteria
Self-identifies as a caregiver of a patient with FD for whom written informed consent has
been obtained for inclusion in the study

Exclusion Criteria

Patients who are unable or unwilling to give consent for study participation
Patients whose ERT preparation and administration takes place exclusively in the home
Caregiver Exclusion Criteria
setting with no HCP involvement in preparation of the infusion
For the time and motion evaluation: Patients whose ERT is administered by a HCP who
does not consent to be observed
Caregiver (and/or the patient with FD whom they support or care for) is unable or
unwilling to give consent for study participation
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

replacement therapy
agalsidase beta
agalsidase alfa

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note